Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression.

Guy A, Gourdou-Latyszenok V, Le Lay N, Peghaire C, Kilani B, Dias JV, Duplaa C, Renault MA, Denis C, Villeval JL, Boulaftali Y, Jandrot-Perrus M, Couffinhal T, James C.

Haematologica. 2019 Jan;104(1):70-81. doi: 10.3324/haematol.2018.195321. Epub 2018 Aug 31.

2.

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis.

Sevin M, Kubovcakova L, Pernet N, Causse S, Vitte F, Villeval JL, Lacout C, Cordonnier M, Rodrigues-Lima F, Chanteloup G, Mosca M, Chrétien ML, Bastie JN, Audia S, Sagot P, Ramla S, Martin L, Gleave M, Mezger V, Skoda R, Plo I, Garrido C, Girodon F, de Thonel A.

Nat Commun. 2018 Apr 12;9(1):1431. doi: 10.1038/s41467-018-03627-9.

3.

Endothelial JAK2V617F does not enhance liver lesions in mice with Budd-Chiari syndrome.

Poisson J, Hilscher MB, Tanguy M, Hammoutene A, Boulanger CM, Villeval JL, Simonetto DA, Valla D, Shah VH, Rautou PE.

J Hepatol. 2018 May;68(5):1086-1087. doi: 10.1016/j.jhep.2018.01.010. Epub 2018 Jan 31. No abstract available.

PMID:
29360553
4.

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Bartalucci N, Calabresi L, Balliu M, Martinelli S, Rossi MC, Villeval JL, Annunziato F, Guglielmelli P, Vannucchi AM.

Oncotarget. 2017 May 22;8(57):96710-96724. doi: 10.18632/oncotarget.18073. eCollection 2017 Nov 14.

5.

Endothelial-to-Mesenchymal Transition in Bone Marrow and Spleen of Primary Myelofibrosis.

Erba BG, Gruppi C, Corada M, Pisati F, Rosti V, Bartalucci N, Villeval JL, Vannucchi AM, Barosi G, Balduini A, Dejana E.

Am J Pathol. 2017 Aug;187(8):1879-1892. doi: 10.1016/j.ajpath.2017.04.006.

6.

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R, Constantinescu SN, Plo I, Vainchenker W.

Blood. 2016 Mar 10;127(10):1317-24. doi: 10.1182/blood-2015-11-679571. Epub 2015 Nov 25.

7.

JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.

Debeurme F, Lacout C, Moratal C, Bagley RG, Vainchenker W, Adrian F, Villeval JL.

J Cell Mol Med. 2015 Nov;19(11):2564-74. doi: 10.1111/jcmm.12608. Epub 2015 Jul 14.

8.

p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging.

Hilpert M, Legrand C, Bluteau D, Balayn N, Betems A, Bluteau O, Villeval JL, Louache F, Gonin P, Debili N, Plo I, Vainchenker W, Gilles L, Raslova H.

Stem Cell Reports. 2014 Dec 9;3(6):1085-102. doi: 10.1016/j.stemcr.2014.10.005. Epub 2014 Nov 20.

9.

Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Lamrani L, Lacout C, Ollivier V, Denis CV, Gardiner E, Ho Tin Noe B, Vainchenker W, Villeval JL, Jandrot-Perrus M.

Blood. 2014 Aug 14;124(7):1136-45. doi: 10.1182/blood-2013-10-530832. Epub 2014 Jun 20.

10.

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.

Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, Wang SF, Defour JP, Sangthongpitag K, Villeval JL, Vainchenker W, Constantinescu SN, Lee MA.

J Cell Mol Med. 2013 Nov;17(11):1397-409. doi: 10.1111/jcmm.12156. Epub 2013 Nov 19.

11.

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.

Bartalucci N, Tozzi L, Bogani C, Martinelli S, Rotunno G, Villeval JL, Vannucchi AM.

J Cell Mol Med. 2013 Nov;17(11):1385-96. doi: 10.1111/jcmm.12162. Epub 2013 Nov 17.

12.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Hasan S, Cassinat B, Droin N, Le Couedic JP, Favale F, Monte-Mor B, Lacout C, Fontenay M, Dosquet C, Chomienne C, Solary E, Villeval JL, Casadevall N, Kiladjian JJ, Vainchenker W, Plo I.

Leukemia. 2014 Feb;28(2):460-3. doi: 10.1038/leu.2013.303. Epub 2013 Oct 22. No abstract available.

PMID:
24150219
13.

JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.

Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, Villeval JL.

Blood. 2013 Aug 22;122(8):1464-77. doi: 10.1182/blood-2013-04-498956. Epub 2013 Jul 17.

14.

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.

Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I.

Leukemia. 2013 Nov;27(11):2187-95. doi: 10.1038/leu.2013.102. Epub 2013 Apr 5.

PMID:
23558526
15.

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.

Pecquet C, Diaconu CC, Staerk J, Girardot M, Marty C, Royer Y, Defour JP, Dusa A, Besancenot R, Giraudier S, Villeval JL, Knoops L, Courtoy PJ, Vainchenker W, Constantinescu SN.

Blood. 2012 May 17;119(20):4625-35. doi: 10.1182/blood-2011-08-372524. Epub 2012 Feb 29.

16.

The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.

Gautier EF, Picard M, Laurent C, Marty C, Villeval JL, Demur C, Delhommeau F, Hexner E, Giraudier S, Bonnevialle N, Ducommun B, Récher C, Laurent G, Manenti S, Mansat-De Mas V.

Blood. 2012 Feb 2;119(5):1190-9. doi: 10.1182/blood-2011-01-327742. Epub 2011 Nov 7.

17.

JAK2V⁶¹⁷F/TET2 mutations: does the order matter?

Pronier E, Quivoron C, Bernard OA, Villeval JL.

Haematologica. 2011 May;96(5):638-40. doi: 10.3324/haematol.2011.042846. No abstract available.

18.

Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis.

Evrard S, Bluteau O, Tulliez M, Rameau P, Gonin P, Zetterberg E, Palmblad J, Bonnefoy A, Villeval JL, Vainchenker W, Giraudier S, Wagner-Ballon O.

Blood. 2011 Jan 6;117(1):246-9. doi: 10.1182/blood-2010-07-294447. Epub 2010 Oct 13.

19.

Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation.

Poirault-Chassac S, Six E, Catelain C, Lavergne M, Villeval JL, Vainchenker W, Lauret E.

Blood. 2010 Dec 16;116(25):5670-8. doi: 10.1182/blood-2010-05-285957. Epub 2010 Sep 9.

20.

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.

Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, Vainchenker W, Villeval JL.

Blood. 2010 Aug 5;116(5):783-7. doi: 10.1182/blood-2009-12-257063. Epub 2010 May 14.

21.

Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.

Jedidi A, Marty C, Oligo C, Jeanson-Leh L, Ribeil JA, Casadevall N, Galy A, Vainchenker W, Villeval JL.

Blood. 2009 Aug 27;114(9):1842-51. doi: 10.1182/blood-2008-09-176875. Epub 2009 Jul 9.

22.

Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.

Marty C, Chaligné R, Lacout C, Constantinescu SN, Vainchenker W, Villeval JL.

J Biol Chem. 2009 May 1;284(18):11781-91. doi: 10.1074/jbc.M808703200. Epub 2009 Mar 4.

23.

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features.

Cross NC, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughal T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM.

Leukemia. 2008 Nov;22(11):1975-89. doi: 10.1038/leu.2008.231. No abstract available.

PMID:
19002192
24.

Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage.

da Costa Reis Monte-Mór B, Plo I, da Cunha AF, Costa GG, de Albuquerque DM, Jedidi A, Villeval JL, Badaoui S, Lorand-Metze I, Pagnano KB, Saad ST, Vainchenker W, Costa FF.

Leukemia. 2009 Jan;23(1):144-52. doi: 10.1038/leu.2008.275. Epub 2008 Oct 9.

PMID:
18843287
25.

Activating mutations in human acute megakaryoblastic leukemia.

Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP, Penard-Lacronique V, Bernard OA.

Blood. 2008 Nov 15;112(10):4220-6. doi: 10.1182/blood-2008-01-136366. Epub 2008 Aug 28.

26.

JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL, Wiesmuller L, Vainchenker W.

Blood. 2008 Aug 15;112(4):1402-12. doi: 10.1182/blood-2008-01-134114. Epub 2008 May 30.

27.

Distinct effects of the soluble versus membrane-bound forms of the notch ligand delta-4 on human CD34+CD38low cell expansion and differentiation.

Lahmar M, Catelain C, Poirault S, Dorsch M, Villeval JL, Vainchenker W, Albagli O, Lauret E.

Stem Cells. 2008 Mar;26(3):621-9. Epub 2007 Nov 29.

28.

Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm H, Gyapay G, Prum B, Fraser CC, Fischer N, Schwarzwaelder K, Siegler ML, de Ridder D, Pike-Overzet K, Howe SJ, Thrasher AJ, Wagemaker G, Abel U, Staal FJ, Delabesse E, Villeval JL, Aronow B, Hue C, Prinz C, Wissler M, Klanke C, Weissenbach J, Alexander I, Fischer A, von Kalle C, Cavazzana-Calvo M.

J Clin Invest. 2007 Aug;117(8):2225-32.

29.

Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin alpha2beta1, and von Willebrand factor.

Calvo E, Tokumasu F, Marinotti O, Villeval JL, Ribeiro JM, Francischetti IM.

J Biol Chem. 2007 Sep 14;282(37):26928-38. Epub 2007 Jul 24.

30.

Coordinated involvement of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1:CCR8 axis.

Gonzalo JA, Qiu Y, Lora JM, Al-Garawi A, Villeval JL, Boyce JA, Martinez-A C, Marquez G, Goya I, Hamid Q, Fraser CC, Picarella D, Cote-Sierra J, Hodge MR, Gutierrez-Ramos JC, Kolbeck R, Coyle AJ.

J Immunol. 2007 Aug 1;179(3):1740-50.

31.

Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors.

Motté N, Saulnier P, Le Couedic JP, Soria JC, Delaloge S, Boige V, Pautier P, Vainchenker W, Bidart JM, Villeval JL.

Int J Cancer. 2007 Nov 1;121(9):2113-5. No abstract available.

32.

Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.

Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligné R, Lacout C, Auradé F, Villeval JL, Gonin P, Vainchenker W, Giraudier S.

Blood. 2007 Jul 1;110(1):345-53. Epub 2007 Mar 20.

33.

Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.

Gastinne T, Vigant F, Lavenu-Bombled C, Wagner-Ballon O, Tulliez M, Chagraoui H, Villeval JL, Lacout C, Perricaudet M, Vainchenker W, Benihoud K, Giraudier S.

Exp Hematol. 2007 Jan;35(1):64-74.

PMID:
17198875
34.

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K, Macintyre EA, Villeval JL, Vainchenker W, Berger R, Bernard OA, Delabesse E, Penard-Lacronique V.

Blood. 2007 Mar 1;109(5):2202-4. Epub 2006 Oct 26.

35.

New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.

Villeval JL, James C, Pisani DF, Casadevall N, Vainchenker W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):341-51. Review.

PMID:
16810610
36.

Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.

Wagner-Ballon O, Chagraoui H, Prina E, Tulliez M, Milon G, Raslova H, Villeval JL, Vainchenker W, Giraudier S.

J Immunol. 2006 Jun 1;176(11):6425-33.

37.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60. Epub 2006 May 2.

38.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W.

Nature. 2005 Apr 28;434(7037):1144-8.

PMID:
15793561
39.

Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells.

Garçon L, Lacout C, Svinartchouk F, Le Couédic JP, Villeval JL, Vainchenker W, Duménil D.

Blood. 2005 Feb 15;105(4):1448-55. Epub 2004 Oct 26.

40.

Identification of residues within human glycoprotein VI involved in the binding to collagen: evidence for the existence of distinct binding sites.

Lecut C, Arocas V, Ulrichts H, Elbaz A, Villeval JL, Lacapère JJ, Deckmyn H, Jandrot-Perrus M.

J Biol Chem. 2004 Dec 10;279(50):52293-9. Epub 2004 Oct 4.

41.

Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen.

Stephens G, Yan Y, Jandrot-Perrus M, Villeval JL, Clemetson KJ, Phillips DR.

Blood. 2005 Jan 1;105(1):186-91. Epub 2004 Aug 31.

42.

Membrane-bound delta-4 notch ligand reduces the proliferative activity of primitive human hematopoietic CD34+CD38low cells while maintaining their LTC-IC potential.

Lauret E, Catelain C, Titeux M, Poirault S, Dando JS, Dorsch M, Villeval JL, Groseil A, Vainchenker W, Sainteny F, Bennaceur-Griscelli A.

Leukemia. 2004 Apr;18(4):788-97.

PMID:
14990974
43.

Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments.

Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval JL, Jandrot-Perrus M.

J Thromb Haemost. 2003 Dec;1(12):2653-62.

44.

Expression of osteoprotegerin mRNA and protein in murine megakaryocytes.

Chagraoui H, Sabri S, Capron C, Villeval JL, Vainchenker W, Wendling F.

Exp Hematol. 2003 Nov;31(11):1081-8.

PMID:
14585373
45.

A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A.

N Engl J Med. 2003 Jan 16;348(3):255-6. No abstract available.

PMID:
12529469
46.

Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library.

Qian MD, Villeval JL, Xiong X, Jandrot-Perrus M, Nagashima K, Tonra J, McDonald K, Goodearl A, Gill D.

Hum Antibodies. 2002;11(3):97-105.

PMID:
12454370
47.

Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease.

Dorsch M, Zheng G, Yowe D, Rao P, Wang Y, Shen Q, Murphy C, Xiong X, Shi Q, Gutierrez-Ramos JC, Fraser C, Villeval JL.

Blood. 2002 Sep 15;100(6):2046-55.

48.

Cloning, expression, and function of BLAME, a novel member of the CD2 family.

Kingsbury GA, Feeney LA, Nong Y, Calandra SA, Murphy CJ, Corcoran JM, Wang Y, Prabhu Das MR, Busfield SJ, Fraser CC, Villeval JL.

J Immunol. 2001 May 1;166(9):5675-80.

49.

Expression and function of the collagen receptor GPVI during megakaryocyte maturation.

Lagrue-Lak-Hal AH, Debili N, Kingbury G, Lecut C, Le Couedic JP, Villeval JL, Jandrot-Perrus M, Vainchenker W.

J Biol Chem. 2001 May 4;276(18):15316-25. Epub 2001 Jan 16.

50.

Myelofibrosis: experimental models and human studies.

Taskin AL, Cohen-Solal K, Le Couedic JP, Abina MA, Villeval JL, Debili N, Casadevall N, Vainchenker W, Wendling F.

Stem Cells. 1998;16 Suppl 2:155-64. Review.

Supplemental Content

Loading ...
Support Center